PhaseFive initiates research-intensive analysis of Healthcare and Biotechnology companies using groundbreaking scientific intelligence tools. We focus on long/short event-driven opportunities centered on clinical, regulatory and early commercial development.
Our research approach relies on synergizing diverse talents. PhaseFive’s team is built on the knowledge and vast experience of Neurobiochemistry PhDs, Big Data experts and seasoned Life Science investors. Our track record reflects our ability to assess a company’s true fair value at critical stages, looking beyond hype and misunderstood perceptions.
PhaseFive focuses on catalyst events in small-to-medium cap Healthcare companies. These catalyst events include clinical trial outcomes, regulatory procedures and commercial developments.
I am a professional who spends their day looking at securities, swaps, legislation and legal implications on the same. I look for value where it is otherwise not found. EQUITY, DEBT, CDS, ISDAFIX (IR SWAPS) FX. and a major advocate of good corporate governance = better valuations.
Professional investor and overall good guy.
By reading Mako Research reports, you agree to use the information at your own risk. In no event should Mako Research or any affiliated party be liable for any direct or indirect trading losses caused by information contained in the research reports. Research reports are not investment advice or a recommendation or solicitation to transact any securities. Mako Research is not a registered investment advisor. You agree to do your own research and due diligence before making any investment decision with respect to securities covered herein. You should assume that Mako Research stands to profit in the event the issuer’s stock declines. Research reports may contain opinions, which are based upon generally available public information, field research, inferences and deductions through due diligence and analytical processes. All information is believed to be accurate and reliable, and has been obtained from public sources. Mako Research makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information. All expressions of opinion are subject to change without notice, and Mako Research is not obligated to update or supplement any reports or any of the information, analysis and opinion contained in them. You should assume that Mako Research has and/or will submit findings with the Securities Exchange Commission, and other entities that may find the information useful.
Zach is a biotech investor with PhD training in Biochemistry and Molecular Biology. In real life, he is a scientific writer specializing in continuing medical education. He hopes to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
We look for potentially undervalued stocks in biotech, technology, and commodities sectors.
We perform research, and give investment opinions and ideas to buy-side firms from time to time.
We do not discuss unpublished reports, or provide any advanced warning of future reports to others.
We are not advisors.
I am an Senior Biotech Analyst with Zacks Investment Research, Inc. I joined Zacks in February 2014.
Prior to joining Zacks, I was an NRSA Postdoctoral Fellow working in a cancer genetics laboratory.
I received my PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill. I also have my BS and MS in Biochemistry from Virginia Tech.
MD, MBA. Professional experience in clinical research and at a top-tier management consulting firm, advising clients in the pharmaceutical and healthcare PE industry. Successfully invested in biotech for over a decade with a value-based approach
Founder of Slingshot Insights, a company that works to provide retail investors access to professional grade investment research tools not readily at their disposal. As a former analyst at a large hedge fund, I found that as I began trading individual stocks on my own, I missed the research tools available to me when I worked for a large institution. The company was born from this idea and my desire to have access to a resource like SI.
www.SlingshotInsights.com Join for free today and check out our cartoon where "Investor Man" Becomes the Smart Money (and explains what Slingshot Insights can do for your diligence process)
Prior to starting Slingshot Insights, I was an analyst at a large hedge fund where I focused on the pharmaceutical industry creating investment theses driven by primary research. I remain a very active investor in a variety of stocks.
Kerrisdale Capital is a private investment manager that focuses on value and special situations investments. We manage investment partnerships and separately managed accounts.
After spending a dozen years making a big name for herself as a highly respected investigative reporter in the financial arena, Melissa Davis took a chance on her longtime dream in 2015 by becoming her own boss so that she could pour even more time and energy into uncovering the truth about suspicious public companies by conducting the deepest research of her award-winning career. At that point, Ms. Davis had already established herself as a fearless journalist with an impressive talent for exposing corporate fraud. Most recently, she served as the founding editor of TheStreetSweeper, a financial news website dedicated to warning investors about risky stocks that she essentially built from scratch. Under her leadership, TheStreetSweeper soon earned steady applause from some of the biggest names in the business and continued to flourish for years. Prior to launching that well-known website, Ms. Davis spent seven years on the staff of TheStreet.com -- an even more prominent financial outlet founded by "Mad Money" host Jim Cramer -- where she quickly rose to become one of the leading investigative reporters on a large and impressive editorial team. Already the recipient of numerous awards by the time that TheStreet.com hired her away from the largest newspaper in her home state, Ms. Davis went on to land a national prize for enterprise reporting from the Society of American Business Editors and Writers (SABEW) by the time that her tenure there came to an end. Today, she spends her days (and, when necessary, plenty of late nights) trying to do what she has always done the best even better: revealing the dirty secrets about publicly traded companies that investors desperately need -- and inherently deserve -- to know! (She also smothers her adorable granddaughter -- the other great love of her life -- with plenty of hugs and kisses at every available chance.)
The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA). Their published work includes freelance and editorial contributions both print and on-line, clinical and medical research, books and tutorials, as well as contributions to on-line social media. Through these and other activities they were able to collaborate and connect amongst themselves to establish this cadre of like-minded biotech/pharma trading and investing aficionados.
The Team includes:
Chief Scientific Analyst - Jason Chew
Chief Research Analyst - Patrick Crutcher
Chief Medical Analyst - Dr. Tro Kalayjian
CEO & Trading Analyst - Tony Pelz
Research Analyst - Dr. Andrew Goodwin
Research Analyst - Dr. Juan Pedro Rodríguez Serrate
Technical Analyst - Joe Gantoss
Research Analyst - Dr. Steven Murphy
I am the founder of asensio.com a noted short-selling organization recognized as the Pioneer of Activist Short Selling. It has successfully advocated against more than 52 companies that we believed to be misleading investors. Early on the New York Times called asensio.com's work "something radical and remarkable." I am a graduate of the University of Pennsylvania’s Wharton School and went to work in Venezuela during that nation’s economic boom period, which occurred after the Venezuelan government nationalized its domestic petroleum industry. I left Venezuela as government policy began to shift away from free markets to attend Harvard University’s Graduate School of Business where I obtained a Master’s degree in investment management and finance.
Read more about asensio.com's history here: http://www.asensio.com/?page_id=7 Read more about our work at asensio.com.
In 1996, asensio.com began releasing short-focused research on the internet, becoming the first organization of its kind, the innovator of Strong Sell recommendations, and was the first and remains the only SEC and FINRA registered broker-dealer to have focused on short-selling research and trading. Our status as a unique member of FINRA and a pioneer in activist short selling generated conflicts with other FINRA members and FINRA's staff determined to bar me from membership in their private organization. We are constantly attempting to correct this disagreement. Today the firm and the site are independent of FINRA.
A statement pertaining to the FINRA matter is available here http://www.asensio.com/?page_id=7370 A disclosure statement can be found at http://www.asensio.com/?page_id=7374
Asia/U.S. Deep-Value Wide-Moat Stocks is a research service for value investors seeking value stocks with a huge gap between price and intrinsic value, leaning towards deep value balance sheet bargains (i.e. buying assets at a discount e.g. net cash stocks, net-nets, low P/B stocks, sum-of-the-parts discounts) and wide moat stocks (i.e. buying earnings power at a discount in great companies like "Magic Formula" stocks, high quality businesses, hidden champions and wide moat compounders).
Those who believe that the pendulum will move in one direction forever—or reside at an extreme forever— eventually will lose huge sums. Those who understand the pendulum's behavior can benefit enormously. ~ Howard Marks
Investment ideas for Asia/U.S. Deep-Value Wide-Moat Stocks are generated from screens, insider trades, 13Fs, fund manager letters, analyst reports, blogs and forums. The initial ideas sourced are subsequently evaluated using The Cheapness-Safety-Quality (CSQ) framework, applying customized investment checklists to ask the right questions of the investments in question, along the dimension of cheapness, safety and quality. Asia/U.S. Deep-Value Wide-Moat Stocks' value investing philosophy borrows from the wisdom of value investing gurus, using both quantitative screens and qualitative inputs to filter the global stock markets for investment ideas.
http://www.wangchukcapital.com As a value investor, I focus on businesses that I understand and trade at low valuations. If I can’t understand the business, I don’t invest. I identify potential investments by conducting my own research and due diligence on companies that investors appear to have become overly pessimistic about. My strategy is to invest in companies that trade at a discount to my estimate of fair value. I focus on deep value micro and nano-cap companies.
Andrew Walker, CFA, is a portfolio manager at Rangeley Capital LLC with a focus on small cap special situations investments. Mr. Walker also contributes to Sifting the World, a value investing forum.
In 2008, Derek Pilecki founded Gator Capital Management (http://www.gatorcapital.com). At Gator, Derek is a Portfolio Manager and is the firm's Managing Member. Gator Capital Management serves as the advisor to the Gator Focus Fund. He can be reached at firstname.lastname@example.org.
From 2003 through 2008, Derek was a co-Chair of the Investment Committee and a Portfolio Manager for Goldman Sach’s Growth Equity Team, where he helped to manage $30 billion in high quality growth stocks. Derek was also a member of the portfolio management team responsible for the Goldman Sachs Capital Growth Fund, and provided primary coverage of the financial sector for the Growth Team.
Prior to Goldman, Derek was an Analyst at Clover Capital Management in Rochester, New York and Burridge Growth Partners (now part of Essex Investments) in Chicago, Illinois. Before entering graduate school, Derek worked at Fannie Mae providing risk analysis for the company’s mortgage investment portfolio.
Derek holds an MBA with honors in Finance and Accounting from the University of Chicago and a BA in Economics from Duke University.
I am a student of the market, and have been blessed to make a living doing my hobby - researching and investing in stocks. I am a patient, long-term investor who likes to capitalize on misperceptions, short-term dislocations, and an occasional risky stock too unsavory for polite company, but with sufficient upside to warrant taking the risk.